Valuation: PolyPid Ltd.

Market Cap 76.31M 66.97M 62.37M 57.36M 108M 7.29B 109M 740M 290M 3.62B 286M 280M 12.49B P/E 2026 *
-4.41x
P/E 2027 * -3.35x
Enterprise Value 76.31M 66.97M 62.37M 57.36M 108M 7.29B 109M 740M 290M 3.62B 286M 280M 12.49B EV / Sales 2026 *
5.09x
EV / Sales 2027 * 8.89x
Free-Float
78.77%
Yield 2026 *
-
Yield 2027 * -
1 day-5.78%
1 week+0.27%
Current month-26.18%
1 month-21.05%
3 months-15.35%
6 months-20.55%
Current year-13.59%
1 week 3.71
Extreme 3.713898
4.3
1 month 3.65
Extreme 3.65
5.73
Current year 3.65
Extreme 3.65
5.73
1 year 3.06
Extreme 3.06
5.73
3 years 2.3
Extreme 2.3
12
5 years 2.3
Extreme 2.3
289.2
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 2022-06-30
Director of Finance/CFO 39 -
Chief Tech/Sci/R&D Officer 61 2025-08-17
Director TitleAgeSince
Director/Board Member 84 2008-03-31
Director/Board Member 52 2022-08-07
Director/Board Member 74 2018-11-30
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Free

Chief Executive Officer

149,000 1.4621%
7/15/26 Free

Director

9,132 0.0896%
7/15/26 Free

Director

9,132 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
-5.78%+0.27%+3.02%-63.25% 76.31M
+1.93%+3.85%+51.05%+166.24% 1,068B
+0.29%+6.43%+60.47%+52.87% 641B
+2.45%+2.77%+39.61%+74.48% 454B
+2.17%+10.22%+41.17%+36.56% 351B
+1.46%+3.87%+39.70%+44.49% 299B
+0.40%+3.59%+19.93%+17.02% 266B
+2.73%+3.50%-25.66%-36.53% 220B
+4.48%+7.33%+30.47%+66.31% 203B
+2.91%+3.10%+18.84%+74.76% 162B
Average +1.39%+1.79%+27.86%+43.30% 366.34B
Weighted average by Cap. +1.96%+4.79%+39.98%+80.09%

Financials

2026 *2027 *
Net sales 15M 13.16M 12.26M 11.27M 21.14M 1.43B 21.5M 145M 56.92M 711M 56.31M 55.1M 2.46B 8.58M 7.53M 7.01M 6.45M 12.09M 820M 12.3M 83.21M 32.57M 407M 32.22M 31.52M 1.4B
Net income -18.96M -16.64M -15.5M -14.25M -26.72M -1.81B -27.18M -184M -71.96M -898M -71.19M -69.65M -3.1B -27.7M -24.31M -22.64M -20.82M -39.03M -2.65B -39.7M -269M -105M -1.31B -104M -102M -4.53B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change Volume
26-07-28 US$3.750 -5.78% 139,611
26-07-27 US$3.980 +2.05% 91,139
26-07-24 US$3.900 -8.02% 286,505
26-07-23 US$4.240 +6.00% 302,140
26-07-22 US$4.000 +6.95% 439,231
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.750USD
Average target price
12.00USD
Spread / Average Target
+220.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock